

FOR IMMEDIATE RELEASE

Clinical Data Strengthens Operational Leadership

William Vernier Appointed Vice President of Operations, PGxHealth[™]

NEWTON, Mass. – February 12, 2008 – Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, today announced the appointment of industry veteran William (Bill) Vernier to the new position of Vice President of Operations for its PGxHealth[™] division, effective immediately.

In this role, Mr. Vernier will be responsible for overseeing the optimization and expansion of key operational functions. Mr. Vernier's skills will be vital as PGxHealth's *FAMILION[™]* and PGxPredict[™] genetic tests become more widely adopted in the United States and abroad and as the Company continues to invest in the advancement of biomarkers for its predictive testing and targeted therapeutics businesses. His responsibilities will include management of all PGxHealth sites, lab operations, customer and provider services, billing and reimbursement, and information systems and technology.

Mr. Vernier, 50, is a veteran of Quest Diagnostics, Inc. where he was most recently a Managing Director responsible for all Quest Diagnostic's operations in the state of Nevada. In this role, Mr. Vernier implemented process discipline throughout his organization resulting in significant improvements in service levels and productivity, which in turn enhanced scalability and profitability. He holds a Six Sigma Master Black Belt and has been responsible for executing Quest Diagnostics' Six Sigma operations across Nevada, Arizona, and the Pacific Northwest. Mr. Vernier received a B.S. in Medical Technology from the University of North Texas and is a registered Medical Technologist with the American Society for Clinical Pathology.

"Bill is an extremely talented individual and an acknowledged leader. He has a track record of building operations to last as well as driving quality improvement and operating efficiencies," said Drew Fromkin, President and CEO of Clinical Data. "Bill's extensive operations experience, process and metric oriented mindset, and high personal standards and work ethic will be critically important to the success of PGxHealth as we continue to build value with the development, introduction and adoption of new predictive tests and targeted therapeutics."

About PGxHealth[™]

PGxHealth is a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers. This division of Clinical Data has extensive experience and capabilities in the development, clinical validation and delivery of genetic tests that assist providers in targeting efficacious and safe drugs for their patients. PGxHealth also leverages its capabilities and intellectual property to develop therapeutics which are targeted at patient subpopulations where drug response is enhanced. Through its know-how and resources, work conducted with some of the world's most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers as *Therapeutic Diagnostics[™]*. For more information about PGxHealth, please visit its website at www.pgxhealth.com.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare™. Its PGxHealth™ division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics™ division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information.

For More Information

Clinical Data, Inc.

EVC Group, Inc.

Julie Huang (investors)

+1-646-443-6963

Matthew Selinger (investors)

+1-415-896-6817

Steve DiMattia (media)

+1-646-201-5445

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our PGxPredict™ tests, including but not limited to FAMILION, will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward

looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2007, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2007, and Current Reports on Form 8-K filed from time to time by the Company.

###